Immune thrombocytopenic purpura

Lore & Background

The pathogenesis of ITP involves antibodies against platelet surface antigens such as glycoproteins IIb-IIIa or Ib-IX, which are of the immunoglobulin G type. The Harrington–Hollingsworth experiment established the immune pathogenesis. Coating of platelets with IgG renders them susceptible to opsonization and phagocytosis by splenic macrophages and Kupffer cells in the liver. Recent research indicates that thrombopoietin levels are normal or elevated in ITP, and thrombopoietin receptor agonists are used to stimulate platelet production.

Reader's Guide

ITP is a significant disorder because it represents a common cause of thrombocytopenia and bleeding risk, particularly in children and adults. Diagnosis requires exclusion of secondary causes such as medications, viral infections, malignancy, and autoimmune conditions. Treatment is not always necessary; for mild cases, observation may suffice. When platelet counts are very low or bleeding occurs, corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, or immunosuppressive medications are used. Refractory ITP, unresponsive to conventional treatment or splenectomy, requires further intervention. The development of thrombopoietin receptor agonists represents a targeted therapeutic advance. The condition's legacy includes its role in demonstrating immune-mediated platelet destruction and the importance of careful diagnostic exclusion.

Did You Know?

• In approximately 60 percent of cases, antibodies against platelets can be detected, most often against glycoproteins IIb-IIIa or Ib-IX.
• Acute ITP often follows a viral infection and is typically self-limited, resolving within 6 to 12 months.
• Platelet transfusions may be used in severe cases with extremely low platelet counts in individuals experiencing bleeding.